Jean-Noel Hugues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Noel Hugues has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Christophe Poncelet
2 shared publicationsChristophe Sifer
Service d'Histologie-Embryologie-Cytogénétique, Laboratoire de Biologie de la Reproduction, Centre Hospitalier Universitaire Jean Verdier, Assistance Publique-Hôpitaux de Paris, Bondy, France
2 shared publicationsI. Cedrin-Durnerin
Reproductive Medicine Unit, Jean Verdier Hospital, University Paris XIII, Paris, France and
2 shared publications- Raphaël Porcher
Paris Cité University Paris France
2 shared publications Afifa Sellami
Laboratoire de Biologie de la Reproduction, Service d’Histologie-Embryologie-Cytogénétique, Bondy, France
1 shared publicationBettina Bständig
University Paris XIII
1 shared publication
Latest Publications
- 31 January 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 95 (1) , 427-430
Biological predictive criteria for clinical pregnancy after elective single embryo transfer
- 31 January 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 95 (1) , 427-430
Biological predictive criteria for clinical pregnancy after elective single embryo transfer
- 30 November 2006
- Published by Elsevier in Fertility and Sterility
- Vol. 86 (5) , 1537-1540
Day 3 compared with day 2 cryopreservation does not affect embryo survival but improves the outcome of frozen-thawed embryo transfers
- 30 November 2006
- Published by Elsevier in Fertility and Sterility
- Vol. 86 (5) , 1537-1540
Day 3 compared with day 2 cryopreservation does not affect embryo survival but improves the outcome of frozen-thawed embryo transfers
- 1 September 2006
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (11) , 2817-2822
The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study
BACKGROUND: In women with chronic anovulation, the choice of the FSH starting dose and the modality of subsequent dose adjustments are critical in controlling the risk of overstimulation. The aim of this prospective randomized study was to assess the efficacy and safety of a decremental FSH dose regimen applied once the leading follicle was 10–13 mm in diameter in women treated for WHO Group II anovulation according to a chronic low-dose (CLD; 75 IU FSH for 14 days with 37.5 IU increment) step-up protocol. METHODS: Two hundred and nine subfertile women were treated with recombinant human FSH (r-hFSH) (Gonal-f) for ovulation induction according to a CLD step-up regimen. When the leading follicle reached a diameter of 10–13 mm, 158 participants were randomized by means of a computer-generated list to receive either the same FSH dose required to achieve the threshold for follicular development (CLD regimen) or half of this FSH dose [sequential (SQ) regimen]. HCG was administered only if not more than three follicles ≥16 mm in diameter were present and/or serum estradiol (E2) values were 2 levels were equivalent in the two groups at the time of hCG administration (441 ± 360 versus 425 ± 480 pg/ml for CLD and SQ protocols, respectively). The rate of mono-follicular development was identical as well as the percentage of patients who ovulated and achieved pregnancy. CONCLUSIONS: The results show that the CLD step-up regimen for FSH administration is efficacious and safe for promoting mono-follicular ovulation in women with WHO Group II anovulation. This study confirms that maintaining the same FSH starting dose for 14 days before increasing the dose in step-up regimen is critical to adequately control the risk of over-response. Strict application of CLD regimen should be recommended in women with WHO Group II anovulation.
- 1 September 2006
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (11) , 2817-2822
The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study
BACKGROUND: In women with chronic anovulation, the choice of the FSH starting dose and the modality of subsequent dose adjustments are critical in controlling the risk of overstimulation. The aim of this prospective randomized study was to assess the efficacy and safety of a decremental FSH dose regimen applied once the leading follicle was 10–13 mm in diameter in women treated for WHO Group II anovulation according to a chronic low-dose (CLD; 75 IU FSH for 14 days with 37.5 IU increment) step-up protocol. METHODS: Two hundred and nine subfertile women were treated with recombinant human FSH (r-hFSH) (Gonal-f) for ovulation induction according to a CLD step-up regimen. When the leading follicle reached a diameter of 10–13 mm, 158 participants were randomized by means of a computer-generated list to receive either the same FSH dose required to achieve the threshold for follicular development (CLD regimen) or half of this FSH dose [sequential (SQ) regimen]. HCG was administered only if not more than three follicles ≥16 mm in diameter were present and/or serum estradiol (E2) values were 2 levels were equivalent in the two groups at the time of hCG administration (441 ± 360 versus 425 ± 480 pg/ml for CLD and SQ protocols, respectively). The rate of mono-follicular development was identical as well as the percentage of patients who ovulated and achieved pregnancy. CONCLUSIONS: The results show that the CLD step-up regimen for FSH administration is efficacious and safe for promoting mono-follicular ovulation in women with WHO Group II anovulation. This study confirms that maintaining the same FSH starting dose for 14 days before increasing the dose in step-up regimen is critical to adequately control the risk of over-response. Strict application of CLD regimen should be recommended in women with WHO Group II anovulation.
- Open Access
- 13 February 2006
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (5) , 1204-1211
Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique—a prospective, randomized, double-blind study
BACKGROUND: In primates, androgens can play a synergistic role with FSH in promoting the early follicular recruitment, which is critical in assisted reproduction technique programmes. OBJECTIVE: To assess whether poor responders can benefit from androgen application. METHODS: Inclusion criteria were a previous poor ovarian response to controlled ovarian stimulation and a decreased hormonal ovarian reserve. Selected women were randomized to receive either transdermal application of testosterone (n = 24) or placebo (n = 25) gel for 15 days before FSH treatment for a second IVF cycle. Similar GnRH analogue and equivalent FSH daily doses were used in both cycles. The primary outcome was the total number of oocytes retrieved. RESULTS: Testosterone gel application resulted in a significant increase in plasma testosterone levels but did not significantly improve the antral follicle count. Furthermore, after gel application, the main parameters of the ovarian response (numbers of pre-ovulatory follicles, total and mature oocytes and embryos) did not significantly differ between testosterone and placebo-treated patients. CONCLUSION: No significant beneficial effects of androgen administration on the ovarian response to FSH could be demonstrated. However, subsequent clinical trials are needed to determine whether an optimal dose and/or a longer duration of testosterone administration may be helpful.
- 13 February 2006
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (5) , 1204-1211
Open AccessEffects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique—a prospective, randomized, double-blind study
BACKGROUND: In primates, androgens can play a synergistic role with FSH in promoting the early follicular recruitment, which is critical in assisted reproduction technique programmes. OBJECTIVE: To assess whether poor responders can benefit from androgen application. METHODS: Inclusion criteria were a previous poor ovarian response to controlled ovarian stimulation and a decreased hormonal ovarian reserve. Selected women were randomized to receive either transdermal application of testosterone (n = 24) or placebo (n = 25) gel for 15 days before FSH treatment for a second IVF cycle. Similar GnRH analogue and equivalent FSH daily doses were used in both cycles. The primary outcome was the total number of oocytes retrieved. RESULTS: Testosterone gel application resulted in a significant increase in plasma testosterone levels but did not significantly improve the antral follicle count. Furthermore, after gel application, the main parameters of the ovarian response (numbers of pre-ovulatory follicles, total and mature oocytes and embryos) did not significantly differ between testosterone and placebo-treated patients. CONCLUSION: No significant beneficial effects of androgen administration on the ovarian response to FSH could be demonstrated. However, subsequent clinical trials are needed to determine whether an optimal dose and/or a longer duration of testosterone administration may be helpful.
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 10, 11-17
Gonadotrophins – filled-by-mass versus filled-by-bioassay
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 10, 11-17
Gonadotrophins – filled-by-mass versus filled-by-bioassay
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 11 (5) , 570-580
Impact of androgens on fertility – physiological, clinical and therapeutic aspects
- 1 January 2005
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 11 (5) , 570-580
Impact of androgens on fertility – physiological, clinical and therapeutic aspects
- 1 November 2004
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 32 (11) , 1007-1008
La fécondation in vitro en France. Approche économique et influence du choix des gonadotrophines (urinaires ou recombinantes) sur le coût : Gynecol Obstet Fertil 2004; 32: 508-518
- 1 November 2004
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 32 (11) , 1007-1008
La fécondation in vitro en France. Approche économique et influence du choix des gonadotrophines (urinaires ou recombinantes) sur le coût : Gynecol Obstet Fertil 2004; 32: 508-518
- 1 January 2004
- Published by Springer Nature in Treatments in Endocrinology
- Vol. 3 (6) , 371-379
Comparative Use of Urinary and Recombinant Human Chorionic Gonadotropins in Women
Human chorionic gonadotropin (hCG) preparations have been widely used as a surrogate for the mid-cycle luteinizing hormone (LH) surge for several decades. The urinary source of hCG preparations was...
- 1 January 2004
- Published by Springer Nature in Treatments in Endocrinology
- Vol. 3 (6) , 371-379
Comparative Use of Urinary and Recombinant Human Chorionic Gonadotropins in Women
Human chorionic gonadotropin (hCG) preparations have been widely used as a surrogate for the mid-cycle luteinizing hormone (LH) surge for several decades. The urinary source of hCG preparations was...
- 31 January 2002
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 30 (1) , 79-85
Débat. LH exogène et stimulation ovarienne
- 31 January 2002
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 30 (1) , 79-85
Débat. LH exogène et stimulation ovarienne